Novartis is set to acquire Avidity Biosciences for over $10 billion, marking the largest acquisition under the leadership of CEO Vas Narasimhan. This deal is expected to expand Novartis' presence in the biotech industry. The acquisition is a significant move in the pharmaceutical sector.